Nedaplatin - CAS 95734-82-0
Catalog number: 95734-82-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C2H8N2O3Pt
Molecular Weight:
303.17
COA:
Inquire
Targets:
Others
Description:
Nedaplatin is a derivative of cisplatin and DNA damage agent for tumor colony forming units with IC50 of 94 μM.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma.
Liang Z1,2, Wang S2, Lin Z3, Feng S4, Cheng Z2, Yang Y1, Kuang Y1, Fidelis C1, Ullah S1, Li F5,6. Cancer Chemother Pharmacol. 2016 Mar;77(3):643-51. doi: 10.1007/s00280-016-2971-4. Epub 2016 Jan 30.
PURPOSE: In this phase I study, single-agent chemotherapy was conducted in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) using nedaplatin (NDP) and concomitant radiotherapy. The study sought to determine the maximum tolerated dose (MTD), recommended dose (RD) and the clinical efficacy of this treatment in locoregionally advanced NPC patients.
2.The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.
Göschl S1, Varbanov HP2, Theiner S3, Jakupec MA4, Galanski M1, Keppler BK3. J Inorg Biochem. 2016 Mar 17. pii: S0162-0134(16)30069-1. doi: 10.1016/j.jinorgbio.2016.03.005. [Epub ahead of print]
The current study aims to elucidate the possible reasons for the significantly different pharmacological behavior of platinum(IV) complexes with cisplatin-, carboplatin- or nedaplatin-like cores and how this difference can be related to their main physicochemical properties. Chlorido-containing complexes are reduced fast (within hours) by ascorbate and are able to unwind plasmid DNA in the presence of ascorbate, while their tri- and tetracarboxylato analogs are generally inert under the same conditions. Comparison of the lipophilicity, cellular accumulation and cytotoxicity of the investigated platinum compounds revealed the necessity to define new structure-property/activity relationships (SPRs and SARs). The higher activity and improved accumulation of platinum(IV) complexes bearing Cl- in equatorial position cannot only be attributed to passive diffusion facilitated by their lipophilicity. Therefore, further platinum accumulation experiments under conditions where active/facilitated transport mechanisms are suppressed were performed.
3.Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Tanaka Y1, Yoshida K1, Tanahashi T1, Okumura N1, Matsuhashi N1, Yamaguchi K1. Cancer Sci. 2016 Apr 7. doi: 10.1111/cas.12943. [Epub ahead of print]
Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin (FP), the prognosis is still unsatisfactory. A new therapeutic regimen combining docetaxel, cisplatin, and 5-Fu (DCF) was recently developed to improve both local and distant tumor control. We developed a new regimen of docetaxel, nedaplatin, and S1 (DGS) and previously reported the recommended dose in a Phase I dose-escalation study. We then performed a phase II study of DGS for advanced esophageal squamous cell carcinoma (SCC). Patients with clinical stage II/III were eligible. Patients received two courses of chemotherapy: docetaxel 35 mg/m2 with nedaplatin 40 mg/m2 on day 8, 80 mg/m2 S1 on days 1-14, and 2 weeks off. After completion of chemotherapy, patients underwent esophagectomy. The primary endpoint was the completion rate of protocol treatment (completion of two courses of preoperative chemotherapy and R0 surgery). We enrolled 32 patients.
4.Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells.
Wang H1, Zhu X1, Huang J1, Chen P2, Han S1, Yan X1. Oncol Lett. 2016 Apr;11(4):2566-2572. Epub 2016 Feb 24.
Cisplatin (DDP) has been one of the most widely used chemotherapy drugs for advanced non-small cell lung cancer. However, the increase in the number of DDP-resistant cancer cells has become a major impediment in the clinical management of cancer. In the present study, for the first time, the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay was used to demonstrate that nedaplatin (NDP) could have a stronger inhibitory effect than DDP alone in DDP-resistant A549 (A549DDP) cells and that it could attenuate the resistance of these cells. Additionally, flow cytometry analysis showed that the apoptosis rate of these resistant cells when exposed to NDP was markedly increased and the number of cells in the G2 stage of the cell cycle was significantly increased. Furthermore, western blot analysis indicated that NDP decreased the protein expression of P-glycoprotein, tumor protein p53 and B-cell lymphoma 2, and increased the expression of Bcl-2-associated X protein, all of which could possibly improve the NDP intracellular drug concentration and promote cell apoptosis.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


GRGDSPK

GRGDSPK, a linear integrin binding peptide, is an inhibitory peptide for RGD-mediated adhesion between integrin and extracellular matrix molecules.

CAS 13450-70-9 CI 600

CI 600
(CAS: 13450-70-9)

CI 600 is a bio-active chemical, but no detailed information has been published yet.

CAS 60166-93-0 Iopamidol

Iopamidol
(CAS: 60166-93-0)

Iopamidol is a nonionic, low-osmolar iodinated contrast agent, developed by Bracco.

Rafigrelide
(CAS: 1029711-88-3)

Rafigrelide is a platelet aggregation inhibitor, which plays a central role in atherothrombotic events. It could prolonge clot formation time and reduce clot st...

CAS 170632-47-0 Lificiguat

Lificiguat
(CAS: 170632-47-0)

Lificiguat, also known as YC-1, is a inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha). YC-1 is widely used as a potent inhibitor of HIF-1alpha both in ...

CAS 102-76-1 Triacetin

Triacetin
(CAS: 102-76-1)

Triacetin, an non-ionic surfactant, could be widely used because of its characteristics like dispersion, emulsification and solubilization capacity. The FEMA nu...

CAS 957230-65-8 Isofagomine D-Tartrate

Isofagomine D-Tartrate
(CAS: 957230-65-8)

The D-Tartrate salt form of Isofagomine, an imino pyranose compound, has been found to be a glucosylceramidase stimulant and could exhibit activity in Gaucher's...

CAS 1350622-33-1 kb-NB77-78

kb-NB77-78
(CAS: 1350622-33-1)

kb-NB77-78 is an analog of CID797718, which is a by-product of the synthesis of the parental compound, CID755673(PKD1 inhibitor).

CAS 3734-33-6 Denatonium benzoate

Denatonium benzoate
(CAS: 3734-33-6)

Denatonium benzoate is a stimulant of the bitter taste receptors used as aversive agents (bitterants) to prevent inappropriate ingestion.

OTS-964
(CAS: 1338545-07-5)

OTS-964, a thienoquinolin derivative, is a TOPK inhibitor and prabably be useful in studying anticancer agent as an analogue of OTS-514. It is still under precl...

CAS 1439399-58-2 CB-839

CB-839
(CAS: 1439399-58-2)

CB-839 an is orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly...

CAS 1704801-24-0 AX-024 hydrochloride

AX-024 hydrochloride
(CAS: 1704801-24-0)

AX-024 hydrochloride is an inhibitor of T cell receptor (TCR) that selectively inhibits the TCR-Nck interaction. By modulating TCR signaling, AX-024 prevents th...

CAS 1632032-53-1 LB-100

LB-100
(CAS: 1632032-53-1)

LB-100 is a water solubleprotein phosphatase 2A (PP2A)inhibitor(IC50= 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells) and enhanced the effects of sorafenib in H...

Desacetylcinobufagin
(CAS: 4026-95-3)

Botanical Source from Bufo bufo gargarizans and Bufo formosus, used for microbial transformation.

GSK-1268992
(CAS: 1414375-49-7)

GSK-1268992 is one of a metabolite of Pazopanib which is a selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits an...

MI-538
(CAS: 1857417-10-7)

MI-538, a 4-methylpyrazole compound, is a double substituted analogue with methylpyrazole at R1 and hydroxyl at R4. MI-538, a potent and selective MLL (Mixed Li...

CAS 157283-66-4 (+)-Cloprostenol isopropyl ester

(+)-Cloprostenol isopropyl ester
(CAS: 157283-66-4)

(+)-Cloprostenol isopropyl ester is a derivative of cloprostenol which has been found to be a FP receptor agonist as well as a luteolytic agent and could be use...

BMS-505130
(CAS: 468715-83-5)

BMS-505130 is a potent and selective serotonin transport inhibitor with K(i) of 0.18 nM.

CS-M1996
(CAS: 876708-01-9)

CS-M1996 is a 4′-Azidocytidine analogue. It can inhibit Hepatitis C virus replication.

CAS 4382-63-2 PFK15

PFK15
(CAS: 4382-63-2)

PFK15 is a potent and selective 6-phosphofructo-2-kinase (PFKFB3) with IC50 of 207 nM.

Chemical Structure

CAS 95734-82-0 Nedaplatin

Quick Inquiry

Verification code

Featured Items